National Centre of Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.
Biomed Res Int. 2013;2013:739010. doi: 10.1155/2013/739010. Epub 2013 Jan 29.
Since 2001 the Istituto Superiore di Sanità established a quality assurance programme for molecular genetic testing that covers four pathologies: Cystic Fibrosis (CF), Beta Thalassemia (BT), Fragile X Syndrome (FX), and Familial Adenomatous Polyposis Coli (APC). Since 2009 this activity is an institutional activity and participation is open to both public and private laboratories. Seven rounds have been performed until now and the eighth is in progress. Laboratories receive 4 DNA samples with mock clinical indications. They analyze the samples using their routine procedures. A panel of assessors review the raw data and the reports; all data are managed through a web utility. In 2010 the number of participants was 43, 17, 15, 5 for CF, BT, FX, APC schemes respectively. Genotyping results were correct in 96%, 98.5%, 100%, and 100% of CF, BT, FX, and APC samples, respectively. Interpretation was correct in 74%, 91%, 88%, and 60% of CF, BT, FX, and APC reports, respectively; however in most of them it was not complete but a referral to genetic counseling was given. Reports were satisfactory in more than 60% of samples in all schemes. This work presents the 2010 results in detail comparing our data with those from other European schemes.
自 2001 年以来,意大利国家卫生研究院(Istituto Superiore di Sanità)建立了一个涵盖四种疾病的分子遗传学检测质量保证计划:囊性纤维化(CF)、β地中海贫血(BT)、脆性 X 综合征(FX)和家族性腺瘤性息肉病(APC)。自 2009 年以来,这项活动已成为一项机构活动,公共和私营实验室均可参与。迄今为止,已经进行了七轮,第八轮正在进行中。实验室收到带有模拟临床指征的 4 个 DNA 样本。他们使用常规程序对样本进行分析。一组评估员会审查原始数据和报告;所有数据都通过网络工具进行管理。2010 年,CF、BT、FX 和 APC 方案的参与者数量分别为 43、17、15 和 5 个。CF、BT、FX 和 APC 样本的基因分型结果分别正确 96%、98.5%、100%和 100%。CF、BT、FX 和 APC 报告的解释分别正确 74%、91%、88%和 60%;然而,在大多数情况下,解释并不完整,但提供了遗传咨询的建议。在所有方案中,超过 60%的样本报告令人满意。这项工作详细介绍了 2010 年的结果,并将我们的数据与其他欧洲计划的数据进行了比较。